13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Macrolides, fluoroquinolones, doxycycline, and ketolides show a good intrinsic activity against intracellular pathogens which are responsible for a variable percentage of community-acquired pneumonia (CAP). These therapeutic agents all seem effective in treating most cases of CAP caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella spp. Among quinolones, the more recent fluoroquinolones, such as gemifloxacin or moxifloxacin, generally show a better intrinsic activity than the older ones. Among macrolides, azithromycin, and clarithromycin show a better pharmacokinetic profile. Both of them are available in intravenous form. It is quite common for M. pneumoniae and C. pneumoniae to continue to be shed in respiratory secretions, weeks after an effective therapy. The clinical relevance of this finding is not clear since most of these patients have a good outcome. Azithromycin, due to its advantageous pharmacokinetic profile, seems the best option when antibiotic prophylaxis is considered in some epidemiological settings. It has been proved effective in closed M. pneumoniae outbreaks.
Roig
J
J
Pulmonary Division, Hospital Nostra Senyora de Meritxell, 1-13 Fiter Rossell, Escaldes, Andorra AD700. averoig@mypic.ad
Casal
J
J
Gispert
P
P
Gea
E
E
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D004318:Doxycycline / Q000627:therapeutic use; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D048628:Ketolides / Q000627:therapeutic use; D018942:Macrolides / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011778:Q Fever / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D048628:Ketolides; D018942:Macrolides; D004318:Doxycycline